Brief: Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma
04/03/2026 14:20
March 4 (Reuters) - Citius Oncology Inc CTOR.O: CITIUS ONCOLOGY ANNOUNCES PRELIMINARY TOPLINE PHASE 1 DATA FROM STUDY OF LYMPHIR™ (E7777) DOSING PRIOR TO COMMERCIAL CAR‑T THERAPY IN HIGH‑RISK DIFFUSE LARGE B‑CELL LYMPHOMA CITIUS ONCOLOGY INC - LYMPHIR WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED IN PHASE 1 STUDY CITIUS ONCOLOGY INC - PHASE 1 STUDY SHOWS 86% OVERALL RESPONSE RATE, 57% COMPLETE RESPONSE, 29% PARTIAL RESPONSE Source text: ID:nPnbWSxtBa Further company coverage: CTOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Oncology
See all newsU.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
U.S. STOCKS ON THE MOVE-Dycom Industries, Robinhood, Brown-Forman
Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy
Brief: Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar